OnCo
drugsProductNot mapped hereapproved

Bleomycin

Bleomycin is the 'B' in BEP for testicular cancer and ABVD for Hodgkin lymphoma; its unique danger is scarring of the lungs, so lung function is monitored and it is often dropped when safe.

Approved 1973. BEP (testicular; omitted in EP for good-risk patients with lung risk), ABVD (Hodgkin; omitted after negative interim PET in RATHL), Kaposi sarcoma (bleomycin-vincristine in Africa), sclerotherapy of lymphatic malformations and pleurodesis, electrochemotherapy for cutaneous tumours. Cumulative dose limit ~400 units; pulmonary toxicity 10%, fatal in 1-2%.

Loading structure…
|
Bleomycin (A2, the main component) · 2D coordinates (no PubChem conformer)
PubChem
Modality
Glycopeptide antibiotic (DNA-cleaving)
Mechanism
Chelates iron and generates free radicals that cause single- and double-strand DNA breaks; inactivated by bleomycin hydrolase, which is scarce in lung and skin (fibrosis, hyperpigmentation).
Brand / code
Blenoxane
Medicare
Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic.

Commercial insurance
covered on label

Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Not appraisedSearch NICE
Notes
Long-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
NHS England
Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: bleomycin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

1top

Approvals

RegionYearIndication
US1973Squamous cell carcinomas, Hodgkin and non-Hodgkin lymphoma, testicular carcinoma, malignant pleural effusion

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
154 studies11 recruiting62 Phase 239 Phase 3
Search “Bleomycin” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Bleomycin
intervention: Bleomycin
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Bleomycin" OR ABSTRACT:"Bleomycin" OR TITLE:"Blenoxane" OR ABSTRACT:"Blenoxane") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bleomycin, not a curated reading list.

Connected

7top

Pages like this

not linked directly; found by shared links